AbCellera's shares jumped as much as 41% on Monday after the company said its experimental injection for hot flashes worked in a mid-stage trial. By shortly before noon Monday, the stock traded 32% higher at $9.17.
The mid-stage trial enrolled 92 postmenopausal women, split between the drug and a placebo. The company also said none of the reported side effects were serious.
The most common complaints were headaches, fatigue, and reactions where the shot went in. For a group of women who have spent years dealing with sudden heat waves and sleepless nights, that trade-off looks pretty good.
The drug, called ABCL635, works by blocking a biological signal that triggers hot flashes. That matters because it is completely non-hormonal. AbCellera's CEO Carl Hansen said, "The hormone therapies currently available are unsuitable for 20% of women."
CEO Carl Hansen did not hold back on a Monday conference call with investors. He said the results were better than his most optimistic expectations and that the efficacy data went beyond any upside scenario the company had dared to consider.
Get the free Always Be Buying eBook and learn the simple system for building wealth on any income
He also used a word Wall Street loves: blockbuster. "We believe ABCL635 has potential to be a blockbuster product," Hansen said.
That is not a wild claim. Hot flashes affect most women going through menopause, and the current standard treatments involve hormones that many women cannot safely take. A drug that works without hormones opens up a huge pool of potential patients.
The market for menopause treatments is large because the problem is common. Most women going through menopause deal with hot flashes, and the standard hormone-based options are not safe for everyone. If ABCL635 continues to prove out, it would give doctors a non-hormonal choice for those patients.
AbCellera has been around for a while, even if you have not heard of it. The company went public in December 2020 and helped develop a Covid-19 therapy during the pandemic. It also has an interesting backstory: Peter Thiel, the billionaire co-founder of Palantir Technologies, was an early investor and served on the board until 2024.
But the company has not always been a market darling. Biotech stocks are known for swinging wildly on news, and AbCellera is no exception. Big expectations bring big risk if a later trial fails.
Here is where things get real. This was a mid-stage trial, which is the second of three phases before a drug can reach the market. That means the data still needs to be confirmed in a larger, longer study, and the company has not shared a timeline for that next step.
Plenty of drugs that look great in mid-stage trials stumble later. The FDA requires proof that a treatment works and is safe in a much bigger group of people, and that takes time. A realistic view is that even if everything goes perfectly, ABCL635 is years away from pharmacy shelves.
Investors who bought the stock at its earlier lows are sitting on a nice gain right now, and calls from analysts suggest more upside could come. The company is also working on other treatments, which spreads out the risk a little.
But for everyday investors, the lesson is simpler. A blockbuster drug that has not finished its testing is still an unproven drug. The science looks promising, and the market for a non-hormonal hot-flash treatment is enormous. Yet the stock will likely swing on every new piece of news until the final answer arrives, possibly around August 10, 2026, or later.
The real question is not whether AbCellera can make a good drug. It is whether the company can keep beating expectations when the stakes get even higher.
Download the free Always Be Buying eBook and start putting your money to work today